Overview of Endofer

Property	Description
Active ingredient	Iron Dextran
Form	Solution for injection (Injectable preparation)
Pharmacological class	Anti-anemic agent (Hematinic)
Common use	Replenishment of iron stores
Origin	Synthetic/Derived Polysaccharide Complex

Endofer is a specialized prescription-only medicine whose fundamental identity is defined by its active component, Iron Dextran, and its official classification as an anti-anemic agent. It functions specifically as a hematinic, a type of trace element preparation utilized to address deficits of iron in the body. The medication is distinctively delivered as an injectable preparation, making it suitable for patients requiring rapid or high-dose iron therapy.

What Type of Medicine is Endofer?

Endofer belongs to the pharmacological class of anti-anemic agents, which are medications used to treat or prevent anemia by increasing the hemoglobin level. The medicine is supplied as a sterile solution for injection intended for parenteral administration (intramuscular or intravenous). This method of administration is clinically recognized for providing effective iron repletion when the patient cannot adequately absorb iron orally due to specific medical conditions or severe deficiency.

The Composition and Form of Iron Dextran

The sole active ingredient is Iron Dextran, a synthetic/derived complex which is chemically a stable, non-ionic colloidal solution. This preparation consists of Ferric Hydroxide, the iron source, tightly bound to a Dextran (polysaccharide) carrier. This colloidal structure is a key differentiating factor, as it ensures a controlled and gradual release of the iron, minimizing potential immediate systemic effects often associated with rapid administration of simpler iron salts.

What is the General Purpose of Endofer?

The general purpose of Endofer is to supply a high, accessible dose of iron to effectively restore the body’s essential reserves when they are severely depleted. By providing this iron, the medication provides the necessary component for robust hemoglobin synthesis and the subsequent stimulation of erythropoiesis. The clinical utility of this form is characterized by the efficacy of parenteral iron in achieving rapid restoration of the body's iron stores. This confirms the general benefit of the medicine in correcting systemic issues caused by profound iron deficiency.

Regulatory References

NIH/MeSH

What side effects are possible with Endofer?

Possible Side Effects and Safety Information

The officially documented safety profile of Endofer (Iron Dextran) is primarily characterized by the risk of serious systemic reactions and a range of commonly observed effects across various physiological systems. The risk of severe, immediate hypersensitivity reactions, including anaphylactic reactions leading to circulatory failure, is a key consideration documented in regulatory sources.

Adverse reactions are classified by frequency and body system. Most Common adverse reactions listed in prescribing information include hypotension (low blood pressure), nausea and vomiting, backache, dizziness, and dyspnea (shortness of breath). These effects fall into the categories of Vascular, Gastrointestinal, Musculoskeletal, and Respiratory disorders.

Specific time-related safety patterns are noted, where reactions such as arthralgia, fever, and headache may be delayed, appearing 1 to 2 days after large intravenous administration and typically subsiding within four days. Furthermore, the medicine is contraindicated in individuals with existing evidence of iron overload (hemosiderosis) or anemias not related to iron deficiency. For pregnant patients, severe maternal adverse reactions have been documented to carry a risk of causing fetal bradycardia during the second and third trimesters, which is a key population-specific safety concern.

Overdose and Emergency Response

The official regulatory profile for Endofer (Iron Dextran) identifies two primary domains for overdose: acute, life-threatening reactions and long-term iron overload resulting from excessive therapy.

Acute Manifestations and Emergency Action

Acute overdose exposure may present as severe, anaphylactic-type reactions documented in official labeling. These manifestations include sudden cardiovascular collapse, severe hypotension, respiratory difficulty (dyspnea), and, in rare instances, cardiac arrest and reported fatalities.

For any manifestation of collapse, seizure, or trouble breathing, immediate medical attention is required, and the instruction is to contact emergency services immediately. The administration of Endofer mandates that resuscitation equipment and personnel trained for anaphylactic shock must be readily available. Furthermore, the infusion must be stopped immediately upon the onset of a severe reaction.

Chronic Overload and Monitoring

Overdose resulting from excessive, prolonged therapy may lead to iron overload, specifically documented as potential iatrogenic hemosiderosis in prescribing information. To prevent this outcome, official regulatory documents require the periodic monitoring of hematologic and iron parameters. An increased risk of toxicity requires monitoring consideration in patients with severe liver function impairment. Additionally, severe reactions in pregnant women have been associated with fetal bradycardia.

Therapeutic Uses of Endofer

What Endofer Treats: Main Uses and Benefits

Endofer is used for conditions presenting with disruptive symptom manifestations related to severe iron deficits, particularly Severe Iron Deficiency Anemia (IDA). This therapy is specifically relevant for easing the symptom burden in patients who have intolerance to oral iron or an unsatisfactory response to standard oral treatment. It is applied across therapeutic domains where additional symptomatic support is needed due to conditions involving inflammatory or irritative processes, such as Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD), which often necessitate additional iron support.

The use is focused on addressing symptom clusters that may become intense or disruptive, including profound fatigue, generalized weakness, and associated cardiopulmonary stress. This approach assists with maintaining functional stability by supporting iron repletion when the intestinal absorption pathway is compromised.

“The therapy is considered relevant when symptomatic assistance is needed due to conditions where the body may struggle with oral iron absorption.”

Quick Fact: Support for Profound Fatigue

The medication is commonly used to help with symptoms related to systemic imbalance, supporting general well-being during symptomatic phases where profound tiredness interferes with daily functioning.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Endofer

Endofer (Iron Dextran Injection) is regulated for use only in specific patient populations, with eligibility strictly defined by the patient’s iron status, age, and existing medical conditions.

Who Must Not Use Endofer (Contraindications)

Endofer is contraindicated in patients with a known hypersensitivity to Iron Dextran or any component of the product. Use is also strictly prohibited in patients with iron overload (such as hemosiderosis or hemochromatosis) and in patients with anemias not associated with iron deficiency.

Populations Allowed and Restricted Use

Population Group	Regulatory Status
Eligible Patients	Adults and pediatric patients age 4 months and older with documented Iron Deficiency Anemia who have failed or cannot tolerate oral iron.
Pediatric Restriction	Not recommended for use in infants under 4 months of age.
Hepatic Function	Use requires extreme caution in patients with serious impairment of liver function.
Pregnancy	Use is permitted only if the potential benefit justifies the potential risk to the fetus. Caution is advised during lactation.

Use is also restricted and requires special caution in patients with a history of severe allergies, asthma, or pre-existing cardiovascular disease. Similarly, patients with active Rheumatoid Arthritis must use the medicine with extreme care.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Endofer, which is an intravenous iron preparation, has an officially documented interaction profile primarily focused on its effect on co-administered oral iron preparations and its acute impact on laboratory testing procedures.

Regulatory documents state that, similar to other parenteral iron products, Endofer may be expected to reduce the absorption of oral iron medicines when they are taken concurrently. This anticipated effect on absorption warrants careful management when transitioning a patient from intravenous to oral iron therapy, although specific clinical studies on this drug have not been extensively published in regulatory documents.

Interaction-Related Procedural Constraints

The product's administration creates a specific constraint regarding laboratory testing. Following an intravenous dose of Endofer, serum iron measurements should not be performed for at least 48 hours. This restriction is necessary because the administration of Endofer causes a rapid and temporary increase in Transferrin Saturation (TSAT) values, which could lead to inaccurate or misleading test results if measurements are taken too soon. This constraint is a formal requirement for monitoring patients who receive this treatment.

Summary of Documented Interactions

Interacting Product Category	Nature of Interaction	Implication/Management
Oral Iron Preparations	Reduced absorption of oral agent	Caution/Avoidance during intravenous treatment
Serum Iron Measurements (TSAT)	Transient increase in values	Delay testing for at least 48 hours post-dose

Mechanism of Action

How Endofer Works

Targeted Iron Delivery and Systemic Transport

Endofer is an iron complex that acts as a substrate, providing iron for integration into the circulatory system. This mechanism involves the reticuloendothelial system releasing the iron, which is subsequently bound by the transport protein transferrin to be distributed to sites of utilization. This action supplies the substrate required for cellular utilization.

Mechanism in Hemoglobin Synthesis

The core mechanistic domain involves the hematopoietic system, directly supplying iron for erythropoiesis in the bone marrow. The iron is channeled to erythroid precursor cells where it is incorporated into hemoglobin, which modifies early molecular steps that shape systemic physiological outcomes. This results in the incorporation of iron into hemoglobin, thereby increasing the oxygen-carrying capacity of the red blood cells.

Provision for Cellular and Tissue Stores

This mechanism extends beyond the blood to influence fundamental cellular metabolic pathways. The drug supplies iron required for the synthesis of myoglobin in muscle and for numerous heme and non-heme enzymes involved in cellular respiration. This mechanism provides iron for storage (ferritin) and synthesis of iron-containing enzymes necessary for cellular metabolism.

Dosage and Administration Information

Administration Overview

Endofer is an iron replacement product administered via intravenous infusion or injection. The administration process is conducted by healthcare professionals in a clinical setting equipped to monitor the patient during and after the procedure.

Preparation and Setting

The medication is typically prepared by diluting the concentrate with a sterile saline solution. Because it is delivered directly into the bloodstream, the procedure takes place in a controlled environment such as a hospital, outpatient clinic, or specialized infusion center.

Infusion Procedure

There are two primary methods for administering this medication:

Intravenous Infusion: The solution is delivered slowly through a drip into a vein. This method usually takes a specific period of time to ensure the iron is processed effectively by the body.
Slow Intravenous Injection: In some cases, the medication may be administered as a direct injection into a vein or into the venous limb of a dialysis circuit.

Observation Period

Following the administration, patients remain under the observation of medical staff. This standard practice allows healthcare providers to monitor for any immediate physical responses to the iron and ensures the patient is stable before leaving the facility.

Treatment Schedule

The frequency and duration of the treatment cycles are determined by a healthcare provider based on individual iron levels and clinical requirements. Periodic blood tests are used to track the body's response to the medication and to guide the ongoing management of the iron deficiency.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Endofer

The evidence base for the active ingredient in Endofer, Iron Dextran, is derived from official research sources, including regulatory evaluations, published clinical trials, and comprehensive systematic reviews. This overview focuses on the structure of that research, describing the specific conditions and outcomes that studies have explored.

Evidence for Severe Iron Deficiency Anemia (IDA) in Oral Iron Failure

Research has specifically studied the use of this medicine in adult patients diagnosed with severe Iron Deficiency Anemia (IDA) who either cannot tolerate or do not respond adequately to iron taken by mouth. The evidence in this area primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews.

These studies mainly examined changes in hematological biomarkers, such as how quickly Hemoglobin levels increased and whether the body's Iron Storage Markers (like Ferritin) were restored. Findings describe patterns observed in the studies where measurable increases in these markers were reported. However, the evidence base includes studies conducted on older iron dextran formulations, and this must be considered when evaluating the relevance of the research. Additionally, long-term effects are not fully established by dedicated RCTs.

Evidence in Iron Deficiency Associated with Chronic Kidney Disease (CKD)

The use of injectable iron for iron deficiency that was associated with Chronic Kidney Disease (CKD) in adult patients not yet on dialysis was evaluated in various research settings, including Observational Studies and trials comparing different intravenous iron products.

These research scenarios monitored the effect on Hemoglobin and Iron Indices in this specific population. Data show patterns related to hematological correction within the observed groups over defined time intervals. Certainty remains low for long-term functional outcomes such as mortality or cardiovascular events, as this data is primarily derived from broader observational reports rather than controlled trials.

Evidence in Special Populations

The research base has been studied for specific populations, including pregnant women with severe IDA. Clinical trials and retrospective cohorts research examined the administration of the medicine in pregnant women. Data are still emerging for this group. The overall certainty remains low because sample sizes were modest in the studies conducted, and large, long-term, controlled trials are limited.

Frequently Asked Questions (FAQ)

Common questions about Endofer (FAQ)

Q: What is Endofer used for besides the main condition?

According to official regulatory documents, this medicine is specifically authorized for the treatment of documented iron deficiency anemia in certain adult and pediatric patients. This includes individuals who have failed to respond adequately to, or cannot tolerate, oral iron. Official indications also describe replacement of the calculated iron deficit resulting from documented blood loss.

Q: Why is Endofer prescribed over other similar treatments?

This form of iron delivery is typically utilized for patients with documented iron deficiency who are either intolerant of or unable to absorb oral iron preparations. It is also considered when there is a clinical need for rapid, high-dose delivery of iron to replenish reserves quickly. Its administration is subject to review for contraindications, such as iron overload.

Q: How long does it typically take to start feeling the effects of Endofer?

Clinical studies have examined the rate of change in hematological markers, such as how quickly Hemoglobin (Hb) levels begin to rise and iron stores are restored. While measurable biological changes in iron markers are reported in studies, the individual patient experience regarding the onset of symptomatic relief can vary.

Q: Are there any long-term side effects associated with Endofer use?

The medicine’s safety profile includes both immediate and delayed adverse reactions, most of which are reported to subside within days after administration. Official regulatory documents indicate that dedicated clinical trials establishing the long-term effects of the active ingredient, Iron Dextran, are limited.

Q: Can I drink coffee or tea while taking Endofer?

Since Endofer is administered by injection or infusion directly into the bloodstream (parenterally) and not taken by mouth, the consumption of coffee or tea is not described in the official product information as a restriction related to the absorption of this medicine.

Q: Is Endofer safe to use if I have kidney problems?

Research evidence has examined the use of injectable iron for iron deficiency associated with Chronic Kidney Disease (CKD) in adults not on dialysis. However, regulatory documents state the medicine should not be used during the acute phase of infectious kidney disease. Use in patients with pre-existing kidney conditions is determined by a healthcare provider.

Q: Is there a generic version of Endofer available?

Endofer is the brand name for the active ingredient Iron Dextran. This ingredient, known as the established or generic name, may be manufactured and marketed by different companies, potentially under various brand names or as a non-branded preparation, subject to local regulatory approval.

Q: How is Endofer different from oral supplements?

Endofer is an injectable preparation used for patients who cannot adequately absorb iron through the gut, or when there is an immediate need for a high dose of iron. Oral iron supplements are typically taken by mouth and absorbed slowly through the digestive tract, an effect that can be influenced by foods or other oral medicines.

Q: Can Endofer change the color of my urine or stool?

Official documents for the active ingredient indicate that the administration of iron dextran has been associated with reports of red or pink urine in some individuals. While iron in general can cause stool to darken, this specific change is not consistently listed as a common adverse reaction in the parenteral product's regulatory label.

Q: Can I take pain relievers like ibuprofen with Endofer?

Official drug interaction documents do not specifically list common pain relievers like Ibuprofen as having a significant interaction with parenteral Iron Dextran. It is important that patients disclose all medications to their healthcare provider.

Q: Can Endofer affect my mood or cause anxiety?

Official regulatory documents list adverse reactions that may include changes in mental status and feelings of restlessness at a rare frequency. Any significant changes in mood or anxiety should be noted and discussed with a healthcare professional.

Q: Is Endofer safe for elderly patients?

Clinical experience has been reported for the use of injectable iron in the elderly population. Regulatory documents do not identify specific cautions or required dose adjustments for use in the elderly beyond those for all adults. Caution is generally advised in patients with underlying health conditions, which may be more common in this age group.

Q: What is the process for getting an Endofer infusion?

The medicine must be administered by a healthcare professional as a slow injection or IV drip infusion. The procedure requires a mandatory small test dose to be given first, followed by observation to ensure the patient tolerates the medicine well. The specific total dose is determined by the healthcare professional based on individual patient parameters.

Q: Are there any major drug interactions with blood pressure medications and Endofer?

Official regulatory documents identify a potential increased risk of hypersensitivity reactions when parenteral iron dextran is used concomitantly with certain classes of blood pressure medications, specifically Angiotensin-Converting Enzyme (ACE) inhibitors. Disclosing all current medications is essential for patient safety.

Q: What are the signs of a severe allergic reaction to Endofer?

The most serious reactions described in the official warnings are of an anaphylactic-type. These can be characterized by the sudden onset of breathing difficulties (e.g., shortness of breath) and/or cardiovascular collapse (e.g., severe low blood pressure or feeling lightheaded).

Q: Is Endofer a high-risk medication?

Regulatory documents carry a Boxed Warning concerning the risk of severe systemic reactions, including fatalities, following administration. Regulatory documents note that administration should take place only where resuscitation equipment and personnel are readily available.

Q: Why is the active ingredient in Endofer sometimes called different names?

The active ingredient is formally known as Iron Dextran, which is the established name (sometimes referred to as the generic or chemical name). Endofer is the brand name or trade name used by a specific manufacturer to market the medicine.

Q: How does Endofer leave the body?

The elemental iron component is either utilized by the body for processes like hemoglobin synthesis or is placed into storage. The dextran complex (the carrier part of the medicine) is then metabolized or primarily eliminated by the kidney over time.

Q: Can Endofer be used by people who follow a vegetarian or vegan diet?

The active ingredient is a complex of Ferric Hydroxide and Dextran (a polysaccharide carrier). Regulatory documents describe this chemical composition but do not explicitly verify the sourcing of all components (such as the derived polysaccharide) for strict vegetarian or vegan compliance.

How should Endofer be stored and disposed of?

Official Storage and Disposal Requirements

Endofer (Iron Dextran Injection) must be stored and handled according to specific regulatory requirements to maintain its stability and integrity.

Requirement	Official Condition (Regulatory Basis)
Storage Temperature	Controlled Room Temperature, between 15 C and 30 C (59 F and 86 F).
Protection Rule	Do not freeze; the product must be protected from freezing.
In-Use Stability	Multiple-dose vials: Use within 90 days after the first puncture. Diluted solution: Use immediately, or store for le 24 hours at 2 C to 8 C.
Container Rule	Keep the container tightly closed and inspect the solution for particles before use.
Child Safety	Must be kept out of the sight and reach of children.
Disposal Rule	Unused medicine and waste material must be disposed of in accordance with local requirements and should not be released into the environment or wastewater systems.

Endofer